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Introduction 
Grafting techniques in vascular surgery are frequently 
complicated by severe infections, associated with mor- 
tality and limb-loss rates of 25--40%, 14 that occur both 
early after implantation of grafts and even much later. 
The severity of these infections is a consequence of
the extremely high resistance of bacterial biofilms 
growing on graft surfaces, due to the production of 
esopolymeric substances. 5-7Several approaches have 
been attempted to overcome this problem, including 
improvement in aseptic surgical techniques, de- 
velopment of new biomaterials intended to be less 
suitable for bacterial colonisation, bonding of anti- 
bacterial agents to grafts by different means, 8ql and 
research for new systemic agents able to disrupt bio- 
films. 12'13 Each different approach resulted in some 
improvement in therapeutic outcomes of grafting pro- 
cedures, but none proved to be a definitive solution. 
The most threatening feature of biofilm growth with 
regard to resistance to antibacterials and host defences 
is certainly the production of glycocalyx. This was the 
target of several studies devoted to the development 
of new therapeutic strategies for prosthetic infections. 
Recently the results of two studies disclosed two po- 
tentially useful strategies to enhance the activity of 
antibiotics on bacterial biofilms, and namely the use 
of proteolytic enzymes 1Band the use of macrolides ~a 
both in association with antibiotics. The present work 
aimed at evaluating in vitro the effect of both pro- 
teolytic enzymes and macrolides, in association with 
different antibiotics and in conjunction, on bacterial 
biofilms formed on different biomaterials commonly 
used in vascular surgery. 
Please address all correspondence to: M. C. Thaller, Istituto di 
Microbiologia, Universita "La Sapienza', P.le Aldo Moro 5, 00185 
Rome, Italy. 
Materials and Methods 
Throughout he study 15 bacterial strains were used: 
five were Staphylococcus aureus (including reference 
strain ATCC 6538P), five were Staphylococcus ep- 
idermidis (including reference strain ATCC 35984), and 
five were Pseudomonas aeruginosa. All strains, except 
the reference ones, were recently isolated from vas- 
cular graft infections, and were identified at the species 
level using the ATB 32 STAPH and API 20NE systems 
(Api System, La Balme Les Grottes, Montalieu Vercieu, 
France). 
The following substances were used as antibacterial 
agents: cefamandole (Sigma Chemical Co., St. Louis, 
MO, U.S.A.), gentamycin (Sigma), vancomycin 
(Sigma), ofloxacin (Sigma~Tau, Pomezia, Italy), az- 
ithromycin (Pfizer Italia, Rome, Italy), and serra- 
tiopeptidase (Takeda Italia, Rome, Italy). All tests in 
sessile conditions of growth were performed in trip- 
licate in the presence of the following biomaterials: 
polystyrene beads, 7mm diameter (The Plastic Ball 
Co., Chicago, IL, U.S.A.), 7 mm long pieces of both 
PTFE (W. L. Gore & Associates Inc., Flagstaff, AZ, 
U.S.A.) and gelseal knitted Dacron grafts (Vascutek 
Ltd., Inchinnan, Scotland). 
Minimal inhibitory concentration (MIC) and min- 
imal bactericidal concentration (MBC) values in three 
different conditions of growth were determined ac- 
cording to a previously published method 7 as follows: 
condition A, dilution tubes were inoculated with 
10 6 cfu/ml; condition B, dilution tubes containing the 
biomaterial were inoculated as for condition A; con- 
dition C, dilution tubes were inoculated with the 
biomaterial colonised with 106cfu/ml equivalents. All 
the inocula were prepared from a single overnight 
broth culture, and were sized by the bioluminescence 
apparatus Lumac biocounter M2500 (Lumac bv, 
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Table 1. MIC and MBC values (/~g/ml) of five antibiotics alone 
and associated with azitromycin at a concentration equal to 25% 
of the MIC or serratiopeptidase 10 U/ml in three different con- 
ditions of growth for Staphylococcus aureus SA1511 (comparable 
results obtained performing tests in conditions B and C with 
polystyrene, PTFE, or Dacron). 
Antibiotic MIC MBC 
A B C A B C 
Cefamandole 3.12 3.12 3.12 6.25 25 >200 
Ofloxacin 0.78 0.78 0.78 1.56 6.25 50 
Gentamycin 1.56 1.56 3,12 3.12 6.25 100 
Vancomycin 0.78 0.78 3.12 3.12 12.5 50 
Azitromycin 0.78 0.78 0.78 3.12 12.5 12.5 
Cefamandole* 3.12 3.12 3.12 6.25 25 100 
Ofloxacin* 0.78 0.78 0,78 1.56 3.12 25 
Gentamycin* 1.56 1.56 3.12 3,12 6.25 50 
Vancomycin* 0.78 0.78 3.12 3.12 6.25 12.5 
Cefamandolet 3.12 3,12 3.12 6.25 12.5 12.5 
Ofloxacin-t 0.78 0.78 0.78 1.56 3,12 12.5 
Gentamycint 1,56 1.56 3.12 3.12 3.12 12.5 
Vancomycint 0.78 0.78 1.56 3.12 6.25 6.25 
Azitromycinf 0.78 0.78 0.78 3.12 6.25 6.25 
* Addition of azitromycin at a concentration equal to 25% MIC. 
t Addition of serratiopeptidase 10 U/ml. 
Landgraaf, The Netherlands) aspreviously described. 14
Tests were performed using scalar two-fold dilutions 
of each antibiotic alone and in association with serra- 
tiopeptidase 10U/ml and azitromycin at a con- 
centration equal to 25% of the previously determined 
MIC value for each test strain, for staphylococci, and 
at 2 ~g/ml for pseudomonas. All tests were performed 
in Mueller Hinton broth (Difco Lab., MI, U.S.A.). 
Results 
The MBC values of all antibiotics for all test strains in 
conditions B and C were much higher than those in 
condition A (Tables 1-3), and when serratiopeptidase 
10 U/ml was added they were significantly reduced. 
The addition of azitromycin at a concentration equal 
to 25% of the MIC value (for Gram-positives) and at 
2 #g/ml for pseudomonas influenced MBC values in 
conditions B and C, but less than serratiopeptidase. 
The most effective association when testing sta- 
phylococci was azitromycin and serratiopeptidase, 
showing only little differences in MBC values in the 
three experimental conditions (Tables 1 and 2). No 
differences were observed in MIC and MBC values of 
all antibiotics, for all test strains in the three ex- 
perimental conditions with the three different bio- 
materials tested (Tables 1-3). 
Table 2. MIC and MBC values (pg/ml) of five antibiotics alone 
and associated with azitromycin at a concentration equal to 25% 
of the MIC or serratiopeptidase 10 U/ml in three different con- 
ditions of growth for Staphylococcus epidermidis SA1378 (com- 
parable results obtained performing tests in conditions B and C 
with polystyrene, PTFE, or Dacron). 
Antibiotic MIC MBC 
A B C A B C 
Cefamandole 50 50 50 100 100 >200 
Ofloxacin 0.39 0,39 1,56 1.56 3.12 50 
Gentamycin 50 50 100 100 100 >200 
Vancomycin 6,25 6.25 12.5 25 25 100 
Azitromycin 0,19 0,39 0.39 1.56 12.5 0 
Cefamandole* 25 25 25 50 50 100 
Ofloxacin* 0.39 0.39 0.39 1,56 1,56 6.25 
Gentamycin* 50 50 50 50 50 100 
Vancomycin* 6.25 6.25 6.25 12.5 12.5 25 
Cefamandolet 25 25 25 25 25 50 
Ofloxacint 0.39 0.39 0.39 1,56 1.56 3.12 
Gentamycint 50 50 50 50 50 50 
Vancomycint 6.25 6.25 6,25 12.5 12.5 12.5 
Azitromycint 0.19 0.39 0,39 1.56 3.12 3.12 
* Addition of azitromycin at a concentration equal to 25% MIC. 
t Addition of serratiopeptidase 10 U/ml, 
Table 3. MIC and MBC values (/lg/ml) of for antibiotics alone and 
associated with azitromycin at a concentration equal to 2/1g/ 
ml, or serratiopeptidase 10 U/ml in three different conditions of 
growth for Pseudomonas aeruginosa PS1347 (comparable results 
obtained performing tests in conditions B and C with polystyrene, 
PTFE, or Dacron). 
Antibiotic MIC MBC 
A B C A B C 
Cefamandole 12.5 25 25 25 50 200 
Ofloxacin 3.12 3.12 3.12 3.12 12.5 100 
Gentamycin 0.78 1.56 1.56 3.12 25 200 
Azitromycin 100 200 200 >200 >200 >200 
Cefamandole* 12.5 12.5 12,5 25 25 100 
Ofloxacin* 3.12 3.12 3.12 3.12 12.5 50 
Gentamycin* 0.78 1.56 1.56 3.12 25 100 
Cefamandolet 12.5 12.5 12,5 25 25 50 
Ofloxacint 3.12 3.12 3,12 3.12 6.25 12.5 
Gentamycinf 0.78 1.56 1.56 3.12 12.5 25 
Azitromycint 100 200 200 200 200 200 
* Addition of azitromycin at a concentration equal to 2 ~tg/ml. 
t Addition of serratiopeptidase 10 U/ml. 
Discussion 
Graft-centred infections are certainly to be considered 
a serious complication i  vascular surgery, both be- 
cause of mortality and morbidity and for difficulties 
encountered in their treatment. 14 Generally, as a con- 
sequence of the bacterial colonisation ofgrafts, surgery 
is required to substitute biomaterials in septic con- 
dition with a higher risk of failure. Efficient pro- 
phylactic and therapeutic protocols are thus needed 
which overcome the extreme resistance of bacteria 
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growing  in b iof i lms to antibiotics. Among the strat- 
egies potent ia l ly  usefu l  for this purpose ,  the search 
for molecu les  able to select ively enhance the act iv i ty 
of ant ib iot ics on b iof i lms seems the most  adequate.  
Recent research showed that both  proteo lyt ic  en- 
zymes  I3 and  macro l ides  12can be useful  for this pur -  
pose. Accord ing  to the data  repor ted  here 
ser ra t iopept idase  hows  an act iv i ty h igher  than az-  
i t romycin,  and this shou ld  be kept  in mind  when 
treat ing infections due  to Gram-negat ive  bacter ia.  
Neverthe less ,  since most  vascu lar  graft  infections are 
due to Gram-pos i t ive  bacter ia  (staphylococci  above 
all), 15 it wou ld  be adv isab le  to associate both  serra- 
t iopept idase  and  az i t romyc in  in the t reatment  of these 
infections. 
Conclusion 
In spite of the fact that  specific adhes ins  for di f ferent 
b iomater ia l s  were  repor ted  in di f ferent bacter ia,  16 our  
data  show c lear ly  that both  the suscept ib i l i ty  of bio-  
f i lms to ant ibiot ics and the enhanc ing  act iv i ty of serra- 
t iopept idase  and macro l ides  are not  s igni f icant ly 
in f luenced by  the nature  of the co lon ised b iomater ia l .  
These results  suggest  that these molecules  interfere 
w i th  fundamenta l  metabol ic  steps invo lved  in the 
resistance mechan ism of biof i lms. Cl inical  studies are 
in progress  to assess the in vivo effect iveness of the 
assoc iat ion of az i th romyc in  and  ser ra t iopept idase  in 
the t reatment  of vascu lar  graft  infect ions due  to Gram-  
pos i t ive  bacter ia.  
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